11 Einträge gefunden

1. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment:Results from the Phase 2 GMMG-DANTE Trial

   1. Leypoldt, Lisa B
   2. Gavriatopoulou, Maria
   3. Besemer, Britta
   4. Salwender, Hans
   5. Raab, Marc S
   6. Nogai, Axel
   7. Khandanpour, Cyrus

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications

   1. Döhner, Hartmut
   2. Weber, Daniela
   3. Krzykalla, Julia
   4. Fiedler, Walter
   5. Wulf, Gerald Georg
   6. Salih, Helmut R
   7. Lübbert, Michael

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma

   1. Stroh, Jacob
   2. Seckinger, Anja
   3. Heider, Michael
   4. Rudelius, Martina
   5. Eichner, Ruth
   6. Schick, Markus
   7. Slawska, Jolanta

   2022 - Forschungsinformationssystem des UKE
4. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

   1. Salwender, Hans
   2. Elmaagacli, Ahmet
   3. Merz, Maximilian
   4. Miah, Kaya
   5. Benner, Axel
   6. Haenel, Mathias
   7. Jehn, Christian

   2021 - Forschungsinformationssystem des UKE
5. Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

   1. Jansen, Lina
   2. Merz, Maximilian
   3. Engelhardt, Monika
   4. Weisel, Katja
   5. Scheid, Christof
   6. Straka, Christian
   7. Langer, Christian

   2020 - Forschungsinformationssystem des UKE
6. Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

   1. Schlenk, Richard F
   2. Weber, Daniela
   3. Fiedler, Walter
   4. Salih, Helmut R
   5. Wulf, Gerald
   6. Salwender, Hans
   7. Schroeder, Thomas

   2019 - Forschungsinformationssystem des UKE
7. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

   1. Salwender, Hans
   2. Bertsch, Uta
   3. Weisel, Katja
   4. Duerig, Jan
   5. Kunz, Christina
   6. Benner, Axel
   7. Blau, Igor W

   2019 - Forschungsinformationssystem des UKE - frei zugänglich
8. Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma

   1. Straka, Christian
   2. Salwender, Hans
   3. Schnabel, Brigitte
   4. Sandherr, Michael
   5. Wandt, Hannes
   6. Hübel, Kai
   7. Scheid, Christof

   2015 - Forschungsinformationssystem des UKE
9. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)

   1. Penack, Olaf
   2. Becker, Carolin
   3. Buchheidt, Dieter
   4. Christopeit, Maximilian
   5. Kiehl, Michael
   6. von Lilienfeld-Toal, Marie
   7. Hentrich, Marcus

   2014 - Forschungsinformationssystem des UKE
10. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.

    1. Straka, Christian
    2. Sandherr, Michael
    3. Salwender, Hans
    4. Wandt, Hannes
    5. Metzner, Bernd
    6. Hübel, Kai
    7. Silling, Gerda

    2011 - Forschungsinformationssystem des UKE
11. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

    1. Kropff, Martin
    2. Bisping, Guido
    3. Schuck, Elke
    4. Liebisch, Peter
    5. Lang, Nicola
    6. Hentrich, Markus
    7. Dechow, Tobias

    2007 - Forschungsinformationssystem des UKE